Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.

Abstract The synthesis and structure–activity relationships of a series of novel interferon inducers are described. Pharmacokinetic studies and efficacy assessment of a series of 8-oxo-3-deazapurine analogues led to the identification of compound 33 , a potent and selective agonist of the TLR7 receptor with an excellent in vivo efficacy profile in a mouse model.